Pan Catherina X, Lee Michelle S, Nambudiri Vinod E
Harvard Medical School, Boston, MA, USADepartment of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
Department of Dermatology, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA 02115, USA Harvard Medical School, Boston, MA, USA.
Ther Adv Vaccines Immunother. 2022 Mar 21;10:25151355221084535. doi: 10.1177/25151355221084535. eCollection 2022.
Herpes zoster (HZ) is a neurocutaneous disease that causes significant morbidity worldwide. The disease is caused by the reactivation of the varicella-zoster virus (VZV), which leads to the development of a painful, vesicular rash and can cause complications such as post-herpetic neuralgia and vision loss. Globally, the incidence of HZ is increasing, and it incurs billions in cost annually to the healthcare system and to society through loss of productivity. With the advent of effective vaccines such as the live attenuated vaccine, Zostavax, in 2006, and more recently the adjuvant recombinant subunit vaccine, Shingrix, in 2017, HZ has become a preventable disease. However, access to the vaccines remains mostly limited to countries with developed economies, such as the United States and Canada. Even among countries with developed economies that license the vaccine, few have implemented HZ vaccination into their national immunization schedules due to cost-effectiveness considerations. In this review, we discuss the currently available HZ vaccines, landscape of HZ vaccine guidelines, and economic burden of disease in countries with developed and developing economies, as well as barriers and considerations in HZ vaccine access on a global scale.
带状疱疹（HZ）是一种在全球范围内导致显著发病的神经皮肤疾病。该疾病由水痘-带状疱疹病毒（VZV）重新激活引起，会导致出现疼痛性水疱皮疹，并可能引发如带状疱疹后神经痛和视力丧失等并发症。在全球范围内，HZ的发病率正在上升，每年因生产力损失给医疗保健系统和社会造成数十亿美元的成本。随着2006年减毒活疫苗Zostavax以及最近2017年的佐剂重组亚单位疫苗Shingrix等有效疫苗的出现，HZ已成为一种可预防的疾病。然而，疫苗的获取大多仍局限于美国和加拿大等发达经济体国家。即使在那些批准该疫苗的发达经济体国家中，由于成本效益方面的考虑，很少有国家将HZ疫苗纳入其国家免疫计划。在本综述中，我们讨论了目前可用的HZ疫苗、HZ疫苗指南的情况、发达经济体和发展中经济体国家的疾病经济负担，以及全球范围内HZ疫苗获取方面的障碍和考量因素。
